Intelligence Feed event · Equity · 2026-10-07

    Vaxcyte Prices $1B Concurrent Offering of Common Stock at $64 and 1.50% 2032 Notes

    Question

    Vaxcyte Prices $1B Concurrent Offering of Common Stock at $64 and 1.50% 2032 Notes

    Direct answer

    Clinical-stage vaccine developer Vaxcyte finalized terms on a $1 billion aggregate financing package. The transaction is divided evenly between a common stock issue and convertible debt securities. The company priced 7.4 million common shares at $64.00 per share, accompanied by pre-funded warrants. Simultaneously, it placed $500 million of convertible senior notes maturing in 2032 at an annual interest rate of 1.50%. The capital injection secures pipeline funding through late-stage trials while immediately impacting secondary market liquidity, borrow demand, and convertible arbitrage hedging structures.

    Original publisher
    Market Ontology
    Evidence through
    2026-10-07
    Published
    2026-10-20
    Revision
    1 · 2026-10-20

    Cite as: Market Ontology, “Vaxcyte Prices $1B Concurrent Offering of Common Stock at $64 and 1.50% 2032 Notes”, revision 1, evidence through 2026-10-07. https://marketontology.com/market-events/2026-10-07/vaxcyte-prices-1b-concurrent-offering-of-common-stock-at-64-and-1-50-2032-notes-9ec5c3

    EQUITY
    Vaxcyte Prices $1B Concurrent Offering of Common Stock at $64 and 1.50% 2032 Notes
    Clinical-stage vaccine developer Vaxcyte finalized terms on a $1 billion aggregate financing package. The transaction is divided evenly between a common stock issue and convertible debt securities. The company priced 7.4 million common shares at $64.00 per share, accompanied by pre-funded warrants. Simultaneously, it placed $500 million of convertible senior notes maturing in 2032 at an annual interest rate of 1.50%. The capital injection secures pipeline funding through late-stage trials while immediately impacting secondary market liquidity, borrow demand, and convertible arbitrage hedging structures.
    PCVX
    Impact
    74
    OCT 7
    SIG
    94%
    PCVX
    Vaxcyte Prices $1B Concurrent Offering of Common Stock at $64 and 1.50% 2032 Notes
    Clinical-stage vaccine developer Vaxcyte finalized terms on a $1 billion aggregate financing package. The transaction is divided evenly between a common stock issue and convertible debt securities. The company priced 7.4 million common shares at $64.00 per share, accompanied by pre-funded warrants. Simultaneously, it placed $500 million of convertible senior notes maturing in 2032 at an annual interest rate of 1.50%. The capital injection secures pipeline funding through late-stage trials while immediately impacting secondary market liquidity, borrow demand, and convertible arbitrage hedging structures.
    → A $1B dual-tranche capital raise at $64.00 per share and 1.50% debt coupon expands PCVX shares outstanding while offering convertible arbitrage funds delta-hedging opportunities in the underlying equity.
    Impact
    Clinical-stage vaccine developer Vaxcyte finalized terms on a $1 billion aggregate financing package. The transaction is divided evenly between a common stock issue and convertible debt securities. The company priced 7.4 million common shares at $64.00 per share, accompanied by pre-funded warrants. Simultaneously, it placed $500 million of convertible senior notes maturing in 2032 at an annual interest rate of 1.50%. The capital injection secures pipeline funding through late-stage trials while immediately impacting secondary market liquidity, borrow demand, and convertible arbitrage hedging structures.
    Affected
    PCVX
    Transmission
    A $1B dual-tranche capital raise at $64.00 per share and 1.50% debt coupon expands PCVX shares outstanding while offering convertible arbitrage funds delta-hedging opportunities in the underlying equity.

    How this development reaches the affected companies

    AssetExposure and channelDirectionEvidence
    PCVXequity dilution and convertible arbitrage short delta hedgingMixed1-5dVaxcyte priced 7.4M shares at $64.00 and $500M in 1.50% 2032 convertible notes.

    Does this development affect your holdings?

    Enter your holdings to check them against this and other recent developments, review the decision that matters most, then set a monitor.

    Check this development against my holdings

    Review your initial audit before choosing ongoing portfolio scanning at $79/month.

    What happened next

    AssetCallBase close+1 day+5 days+20 days
    PCVXMixed66.96 2026-10-07-2.90%PendingPending

    Closing prices from stored daily bars; returns measured from the last close on or before the event date. Not a recommendation.

    No verifiable public source recorded for this card.

    Related

    Check this development against my holdings

    See today's live cards

    Public pages are published 24 hours after the product shows them. Desk shows every catalyst, event and causal reading as it happens, mapped to your holdings.

    Open Desk — $399/month